Overexpression of AMPKα1 Ameliorates Fatty Liver in Hyper- lipidemic Diabetic Rats

5’-AMP-activated protein kinase (AMPK) is a heterotrimeric complex consisting of a catalytic (α) and two regulatory (β and γ) subunits. Two isoforms are known for catalytic subunit (α1, α2) and are encoded by different genes. To assess the metabolic effects of AMPKα1, we examined the effects of overexpression of adenoviral-mediated AMPKα1 in hyperlipidemic type 2 diabetic rats. The Otsuka Long-Evans Tokushima Fatty (OLETF) rat is an established animal model of type 2 diabetes that exhibits chronic and slowly progressive hyperglycemia and hyperlipidemia. Thirty five-week-old overt type 2 diabetic rats (n=10) were administered intravenously with Ad.AMPKα1. AMPK activity was measured by phosphorylation of acetyl CoA carboxlyase (ACC). To investigate the changes of gene expression related glucose and lipid metabolism, quantitative real-time PCR was performed with liver tissues. Overexpression of AMPKα1 showed that blood glucose concentration was decreased but that glucose tolerance was not completely recovered on 7th day after treatment. Plasma triglyceride concentration was decreased slightly, and hepatic triglyceride content was markedly reduced by decreasing expression of hepatic lipogenic genes. Overexpression of AMPKα1 markedly improved hepatic steatosis and it may have effective role for improving hepatic lipid metabolism in hyperlipidemic state.

[1]  B. Viollet,et al.  Understanding the Molecular Basis of the Interaction between NDPK-A and AMPK α1 , 2006, Molecular and Cellular Biology.

[2]  B. Viollet,et al.  Understanding the molecular basis of the interaction between NDPK-A and AMPK alpha 1. , 2006, Molecular and cellular biology.

[3]  B. Viollet,et al.  Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. , 2005, Diabetes.

[4]  D. Bolster,et al.  Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside. , 2005, American journal of physiology. Endocrinology and metabolism.

[5]  D. Wasserman,et al.  5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside causes acute hepatic insulin resistance in vivo. , 2005, Diabetes.

[6]  D. Hardie,et al.  AMP-Activated Protein Kinase: A Master Switch in Glucose and Lipid Metabolism , 2004, Reviews in Endocrine and Metabolic Disorders.

[7]  E. Kraegen,et al.  Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. , 2004, Biochemical and biophysical research communications.

[8]  A. Dobrzyń,et al.  The role of stearoyl-CoA desaturase in body weight regulation. , 2004, Trends in cardiovascular medicine.

[9]  N. Socci,et al.  Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. , 2004, The Journal of clinical investigation.

[10]  J. Friedman,et al.  Stearoyl-CoA desaturase-1 and the metabolic syndrome. , 2003, Current drug targets. Immune, endocrine and metabolic disorders.

[11]  G. Rutter,et al.  Roles of 5'-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. , 2003, The Biochemical journal.

[12]  D. Hardie,et al.  Management of cellular energy by the AMP‐activated protein kinase system , 2003, FEBS letters.

[13]  D. Carling,et al.  Protein kinase inhibitors block the stimulation of the AMP‐activated protein kinase by 5‐amino‐4‐imidazolecarboxamide riboside , 2002, FEBS letters.

[14]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[15]  F. Thong,et al.  The putative roles of adenosine in insulin- and exercise-mediated regulation of glucose transport and glycogen metabolism in skeletal muscle. , 2002, Canadian Journal of Applied Physiology.

[16]  Y. Hellsten,et al.  Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. , 2002, Diabetes.

[17]  Young-Bum Kim,et al.  Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature.

[18]  D. Hardie,et al.  Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. , 2001, Biochemical Society transactions.

[19]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[20]  N. Fujii,et al.  AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle. , 2001, American journal of physiology. Endocrinology and metabolism.

[21]  D. Hardie,et al.  AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes. , 1999, American journal of physiology. Endocrinology and metabolism.

[22]  R. Coleman,et al.  AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. , 1999, The Biochemical journal.

[23]  M. Carlson,et al.  The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? , 1998, Annual review of biochemistry.

[24]  D. Hardie,et al.  The AMP-activated protein kinase--fuel gauge of the mammalian cell? , 1997, European journal of biochemistry.

[25]  D. Hardie,et al.  Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. , 1997, Journal of applied physiology.

[26]  S. Hawley,et al.  5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? , 1995, European journal of biochemistry.

[27]  K. Kawano,et al.  Spontaneous Long-Term Hyperglycemic Rat With Diabetic Complications: Otsuka Long-Evans Tokushima Fatty (OLETF) Strain , 1992, Diabetes.